Changchun Technology Industries Pays $5 Million for Mucosis Stake

Changchun High & New Technology Industries (Group) paid $4.8 million for a 25% interest in Dutch biopharma Mucosis BV. Mucosis is a clinical-stage biotech developing vaccines that can be administered needle-free via the nose or mouth through the mucosal membranes. Changchun is involved in a diverse range of industries, including real estate. Its life science products include generic drugs and biologics as well as TCM preparations. More details.... Share this with colleagues: // //